April 22nd 2024
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Tremelimumab, Durvalumab Combo Shows Promise for Certain Patients with Localized Bladder Cancer
October 25th 2020Combination treatment with tremelimumab and durvalumab was found to be well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who are not eligible for cisplatin-based chemotherapy.
UroCAD Outperforms Urine Cytology in Detecting Urothelial Carcinoma
October 9th 2020This study suggested that the customized bioinformatics workflow, UroCAD, be used as a noninvasive approach for diagnosis and recurrence surveillance in patients with urothelial carcinoma prior to the use of cystoscopy.
Phase 3 CheckMate-274 Meets Primary End Points in Urothelial Carcinoma
September 25th 2020Researchers suggested these results from CheckMate-274 “point to the potential for nivolumab to become a new standard of care in the adjuvant setting, extending disease-free survival for post-surgery patients with muscle-invasive urothelial cancer without the use of chemotherapy.”
Phase 3 EV-301 Trial of Enfortumab Vedotin-ejfv Meets Primary End Point for Urothelial Cancer
September 18th 2020The clinical trial is comparing enfortumab vedotin-ejfv to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with a platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
Proton Pump Inhibitor Use May Impact Response to Atezolizumab in Patients with Bladder Cancer
September 15th 2020In this study, patients with advanced urothelial carcinoma saw worse outcomes with proton pump inhibitor (PPI) use when treated with atezolizumab, compared with those who were not treated with PPIs.
FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer
January 15th 2020The FDA approved enfortumab vedotin-ejfv (Padcev)-the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBC
January 8th 2020The FDA approved pembrolizumab for the treatment of patients with BCG–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.